 Meghan Jeffres
Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Hypersensitivity | 5 | 2021 | 81 | 2.820 |
Why?
| | Penicillins | 5 | 2021 | 57 | 2.280 |
Why?
| | Cefazolin | 3 | 2021 | 18 | 2.210 |
Why?
| | Education, Pharmacy | 7 | 2019 | 119 | 1.950 |
Why?
| | Anti-Bacterial Agents | 9 | 2024 | 1713 | 1.820 |
Why?
| | Schools, Pharmacy | 6 | 2019 | 46 | 1.770 |
Why?
| | Vancomycin | 4 | 2021 | 78 | 1.710 |
Why?
| | beta-Lactams | 3 | 2018 | 28 | 1.210 |
Why?
| | Faculty, Pharmacy | 5 | 2019 | 20 | 1.160 |
Why?
| | Pharmacists | 6 | 2024 | 247 | 1.130 |
Why?
| | Antibiotic Prophylaxis | 3 | 2021 | 101 | 1.020 |
Why?
| | Career Mobility | 4 | 2017 | 68 | 0.960 |
Why?
| | Motion Pictures | 1 | 2024 | 18 | 0.910 |
Why?
| | Career Choice | 4 | 2017 | 207 | 0.860 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 150 | 0.800 |
Why?
| | Communicable Diseases | 2 | 2024 | 145 | 0.760 |
Why?
| | Pharmaceutical Services | 1 | 2022 | 81 | 0.750 |
Why?
| | Clindamycin | 1 | 2021 | 13 | 0.730 |
Why?
| | Hypersensitivity, Immediate | 1 | 2021 | 43 | 0.720 |
Why?
| | Anaphylaxis | 1 | 2021 | 98 | 0.680 |
Why?
| | Students, Pharmacy | 4 | 2019 | 96 | 0.680 |
Why?
| | Play and Playthings | 2 | 2018 | 33 | 0.670 |
Why?
| | Liver Abscess, Pyogenic | 1 | 2019 | 1 | 0.650 |
Why?
| | Professional Role | 2 | 2017 | 156 | 0.640 |
Why?
| | Kidney Diseases | 2 | 2017 | 383 | 0.630 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2019 | 44 | 0.630 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 66 | 0.610 |
Why?
| | Education, Medical | 2 | 2018 | 243 | 0.580 |
Why?
| | Video Games | 1 | 2018 | 22 | 0.580 |
Why?
| | Liability, Legal | 1 | 2018 | 40 | 0.570 |
Why?
| | Malpractice | 1 | 2018 | 38 | 0.570 |
Why?
| | Methicillin Resistance | 2 | 2007 | 18 | 0.550 |
Why?
| | Pneumonia, Staphylococcal | 2 | 2007 | 20 | 0.530 |
Why?
| | Skin Tests | 1 | 2017 | 100 | 0.530 |
Why?
| | Curriculum | 3 | 2019 | 911 | 0.520 |
Why?
| | Cross Infection | 2 | 2007 | 216 | 0.460 |
Why?
| | Bacterial Infections | 1 | 2015 | 235 | 0.430 |
Why?
| | Motivation | 1 | 2018 | 546 | 0.420 |
Why?
| | Staphylococcus aureus | 2 | 2007 | 437 | 0.400 |
Why?
| | Students | 1 | 2018 | 576 | 0.400 |
Why?
| | Staphylococcal Infections | 1 | 2017 | 392 | 0.400 |
Why?
| | Educational Status | 1 | 2014 | 470 | 0.380 |
Why?
| | Health Personnel | 1 | 2018 | 649 | 0.380 |
Why?
| | Ciprofloxacin | 1 | 2011 | 30 | 0.360 |
Why?
| | Antimicrobial Stewardship | 2 | 2024 | 102 | 0.330 |
Why?
| | Urinary Tract Infections | 1 | 2011 | 149 | 0.320 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 246 | 0.300 |
Why?
| | Humans | 27 | 2024 | 129378 | 0.290 |
Why?
| | Retrospective Studies | 10 | 2021 | 14498 | 0.250 |
Why?
| | Problem-Based Learning | 2 | 2019 | 77 | 0.240 |
Why?
| | Stereotyping | 1 | 2024 | 46 | 0.220 |
Why?
| | Incidence | 3 | 2021 | 2641 | 0.220 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 352 | 0.210 |
Why?
| | Social Stigma | 1 | 2024 | 117 | 0.200 |
Why?
| | Drug Storage | 1 | 2022 | 57 | 0.190 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 768 | 0.190 |
Why?
| | Drug Stability | 1 | 2022 | 159 | 0.190 |
Why?
| | Liver Diseases | 2 | 2016 | 289 | 0.190 |
Why?
| | Middle Aged | 9 | 2021 | 31102 | 0.190 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 204 | 0.180 |
Why?
| | Intraoperative Period | 1 | 2021 | 53 | 0.180 |
Why?
| | Aged, 80 and over | 4 | 2021 | 7069 | 0.180 |
Why?
| | Male | 13 | 2024 | 63595 | 0.180 |
Why?
| | Venous Thromboembolism | 2 | 2016 | 284 | 0.180 |
Why?
| | Female | 13 | 2024 | 68686 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 171 | 0.170 |
Why?
| | Adult | 10 | 2021 | 35512 | 0.170 |
Why?
| | Kidney | 1 | 2007 | 1382 | 0.160 |
Why?
| | Temperature | 1 | 2022 | 634 | 0.160 |
Why?
| | Cohort Studies | 4 | 2019 | 5414 | 0.160 |
Why?
| | United States | 3 | 2022 | 13876 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2019 | 139 | 0.150 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 243 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2021 | 282 | 0.140 |
Why?
| | Time Management | 1 | 2017 | 19 | 0.140 |
Why?
| | Cephalosporins | 1 | 2018 | 40 | 0.140 |
Why?
| | Universities | 2 | 2018 | 405 | 0.140 |
Why?
| | Hospital Mortality | 2 | 2015 | 850 | 0.140 |
Why?
| | Occupational Stress | 1 | 2017 | 39 | 0.140 |
Why?
| | Professional Competence | 1 | 2017 | 94 | 0.140 |
Why?
| | Administration, Oral | 1 | 2019 | 785 | 0.130 |
Why?
| | Risk Factors | 5 | 2017 | 9752 | 0.130 |
Why?
| | Aged | 5 | 2021 | 22052 | 0.120 |
Why?
| | Cooperative Behavior | 1 | 2017 | 430 | 0.120 |
Why?
| | Young Adult | 5 | 2018 | 12415 | 0.120 |
Why?
| | Treatment Failure | 1 | 2015 | 339 | 0.120 |
Why?
| | Educational Measurement | 2 | 2014 | 257 | 0.120 |
Why?
| | Hemorrhage | 2 | 2016 | 677 | 0.110 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 221 | 0.110 |
Why?
| | Health Care Costs | 1 | 2017 | 367 | 0.110 |
Why?
| | Interpersonal Relations | 1 | 2017 | 391 | 0.110 |
Why?
| | Patient Readmission | 1 | 2019 | 665 | 0.110 |
Why?
| | Length of Stay | 2 | 2016 | 1124 | 0.110 |
Why?
| | Inpatients | 1 | 2017 | 465 | 0.100 |
Why?
| | Cephalometry | 1 | 2012 | 31 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 2011 | 0.100 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2012 | 30 | 0.100 |
Why?
| | Clinical Protocols | 1 | 2013 | 255 | 0.100 |
Why?
| | Anticoagulants | 2 | 2016 | 636 | 0.100 |
Why?
| | Pharynx | 1 | 2012 | 56 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2019 | 10195 | 0.090 |
Why?
| | Data Collection | 1 | 2014 | 649 | 0.090 |
Why?
| | Drug Resistance, Microbial | 1 | 2011 | 69 | 0.090 |
Why?
| | Logistic Models | 1 | 2015 | 1986 | 0.090 |
Why?
| | Prevalence | 1 | 2017 | 2560 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 5390 | 0.080 |
Why?
| | Hyperglycemia | 1 | 2013 | 328 | 0.080 |
Why?
| | Physicians | 1 | 2018 | 864 | 0.080 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 530 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2737 | 0.070 |
Why?
| | Missouri | 1 | 2006 | 70 | 0.070 |
Why?
| | Biological Availability | 1 | 2006 | 147 | 0.060 |
Why?
| | Area Under Curve | 1 | 2006 | 304 | 0.060 |
Why?
| | Creatinine | 1 | 2007 | 490 | 0.060 |
Why?
| | Survival Analysis | 1 | 2006 | 1272 | 0.050 |
Why?
| | Adolescent | 3 | 2016 | 20378 | 0.050 |
Why?
| | Chronic Disease | 2 | 2016 | 1713 | 0.040 |
Why?
| | Employee Performance Appraisal | 1 | 2017 | 7 | 0.040 |
Why?
| | Work | 1 | 2017 | 17 | 0.040 |
Why?
| | Feedback | 1 | 2017 | 162 | 0.030 |
Why?
| | International Normalized Ratio | 1 | 2016 | 46 | 0.030 |
Why?
| | Diabetic Coma | 1 | 2013 | 1 | 0.030 |
Why?
| | Hypokalemia | 1 | 2013 | 24 | 0.030 |
Why?
| | Nevada | 1 | 2013 | 9 | 0.030 |
Why?
| | Hospitals, University | 1 | 2013 | 178 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2013 | 317 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 398 | 0.030 |
Why?
| | Dental Clinics | 1 | 2012 | 5 | 0.020 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2012 | 10 | 0.020 |
Why?
| | Longevity | 1 | 2013 | 151 | 0.020 |
Why?
| | Teaching Materials | 1 | 2011 | 23 | 0.020 |
Why?
| | Diabetic Ketoacidosis | 1 | 2013 | 197 | 0.020 |
Why?
| | Patient Safety | 1 | 2013 | 286 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 993 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1546 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3375 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2013 | 737 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5061 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3236 | 0.020 |
Why?
| | Sex Factors | 1 | 2012 | 1966 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4415 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1219 | 0.010 |
Why?
| | Blood Glucose | 1 | 2013 | 2096 | 0.010 |
Why?
| | Hospitalization | 1 | 2013 | 2070 | 0.010 |
Why?
| | Insulin | 1 | 2013 | 2325 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2436 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2013 | 3628 | 0.010 |
Why?
| | Child | 1 | 2012 | 20868 | 0.010 |
Why?
|
|
Jeffres's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|